The in vitro data presented thus far strongly suggest that the gefitinib and RAD001 combination exerts beneficial therapeutic effects in HER2 overexpressing breast cancer cell lines, irrespective of their TZ or gefitinib sensitivity status. This evidence concerns the gene ERBB2 and breast carcinoma.